The AGM is largely a routine governance event with no new material financial disclosures beyond what was reported in the Q1 2026 6-K on May 5. The $1.0B buyback is a modest capital return signal but does not offset the declining revenue trajectory. Monitor upcoming oncology pipeline catalysts (pumitamig data readouts) as the primary value driver.
Price Chart
Executive Summary
BioNTech held its 2026 Annual General Meeting, where all agenda items were approved by shareholders, including expanding the Supervisory Board from six to eight members and electing two new members. The AGM presentation reaffirmed FY2026 revenue guidance of $2.0-2.3 billion (non-IFRS) and announced a $1.0 billion share repurchase program over the next twelve months, while highlighting the ongoing transition from COVID-19 vaccine revenues toward a late-stage oncology pipeline.
Key Facts
- Shareholders approved expanding the Supervisory Board from six to eight members and elected Prof. Iris Löw-Friedrich and Dr. Susanne Schaffert as new members.
- FY2026 non-IFRS revenue guidance reaffirmed at $2.0-2.3 billion, down from FY2025 IFRS revenue of $2.87 billion.
- Q1 2026 unaudited IFRS revenues were $118 million, down from $183 million in Q1 2025.
- Q1 2026 IFRS net loss was $532 million ($2.10 per share), compared to a net loss of $416 million ($1.73 per share) in Q1 2025.
- Cash and cash equivalents plus security investments totaled $16.8 billion as of March 31, 2026.
- Announced a share repurchase program of up to $1.0 billion over the next twelve months.
- Manufacturing footprint consolidation expected to achieve approximately $500 million in recurring annual savings by 2029.
- BMS partnership for pumitamig includes $3.5 billion upfront and non-contingent payments plus $7.6 billion in milestone payments.
Financial Impact
FY2026 revenue guidance of $2.0-2.3 billion (non-IFRS) vs FY2025 IFRS revenue of $2.87 billion; Q1 2026 revenue $118M vs $183M YoY; Q1 2026 net loss $532M vs $416M YoY; $16.8B cash position; $1.0B buyback authorized.
Risk Factors
- COVID-19 vaccine revenue continues to decline faster than oncology pipeline can offset.
- FY2026 revenue guidance of $2.0-2.3 billion implies a 20-30% decline from FY2025.
- Operating losses are widening ($677M in Q1 2026 vs $534M in Q1 2025) as R&D spending remains elevated.
- Competitive dynamics in the US COVID-19 vaccine market and transition away from multi-year European contracts create revenue uncertainty.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001776985-26-000035 |
| Document: form6-k2026agm15may2026.htm | 0001776985-26-000035 |
| Document: a99120260515_bntxxagmxenxf.htm | 0001776985-26-000035 |
| Document: a993votingresults.htm | 0001776985-26-000035 |
| Document: 0001776985-26-000035-index-headers.html | 0001776985-26-000035 |
| Document: 0001776985-26-000035-index.html | 0001776985-26-000035 |
| Document: 0001776985-26-000035.txt | 0001776985-26-000035 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 6-K | $98.86 $98.00 | ▼ −0.87% | ▼ −0.98% | $96.61 (−2.28%) |
Sep 14, 2026 18d ago | Press Release | $98.86 $98.00 | ▼ −0.87% | ▼ −0.98% | $96.61 (−2.28%) |
Aug 28, 2026 5w ago | 6-K | $102.08 $103.76 | ▼ −1.65% | ▼ −1.54% | $96.61 (+5.36%) |
Aug 20, 2026 6w ago | 6-K | $110.89 $111.40 | ▲ +0.46% | ▼ −0.65% | $96.61 (−12.88%) |
Aug 11, 2026 7w ago | Institutional Cluster | $92.80 $92.75 | ▼ −0.05% | ▲ +0.35% | $96.61 (+4.10%) |
Aug 4, 2026 8w ago | 6-K | $91.35 $92.80 | ▼ −1.59% | ▼ −1.69% | $96.61 (−5.75%) |
Aug 3, 2026 8w ago | 6-K | $92.25 $92.80 | ▲ +0.60% | ▼ −1.43% | $96.61 (+4.72%) |
Aug 3, 2026 8w ago | Press Release | $92.25 $92.80 | ▲ +0.60% | ▼ −1.43% | $96.61 (+4.72%) |
Jul 29, 2026 9w ago | 6-K | $92.85 $91.19 | ▼ −1.79% | ▼ −5.41% | $96.61 (+4.04%) |
Jun 8, 2026 16w ago | 6-K | $85.50 $90.80 | ▲ +6.20% | ▲ +4.09% | $96.61 (+12.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access